7-[3-(4-fluorophenyl) -1-(1-methylethyl) -1H-indol-2-yl]-3, 5-dihydroxy-hept-6-enoic acid

Absorption
Absolute bioavailability is 9% to 50%. The relative bioavailability for the extended-release (ER) form is 9% to 66%. T max is less than 1 h. C max is 48.9 to 990 ng/mL.

Immediate-release
Administration with food at steady state increases T max and decreases C max .

ER
Administration with a high-fat meal increases bioavailability by about 50%.

Distribution
Fluvastatin is 98% protein bound. The mean Vd at steady state is about 0.35 L/kg.

Metabolism
No active metabolites are present systemically. The drug is metabolized in the liver primarily via hydroxylation; oxidation occurs via CYP2C9 isozyme systems (75%), 3A4 (about 20%), and 2C8 (about 5%).

Elimination
About 90% is excreted in feces as metabolites, and less than 2% is unchanged. The t ½ is less than 3 h.

Special Populations
Hepatic Function Impairment

AUC and C max increase 2.5-fold.

胃腸不適, 頭痛, 失眠, 過敏反應 ,肝炎 ,肌肉痛, 無力

Azole antifungal agents (eg, fluconazole), cyclosporine, gemfibrozil, macrolide antibiotics (eg, erythromycin), niacin
Severe myopathy or rhabdomyolysis may occur with coadministration.

Cholestyramine
Reduced absorption of fluvastatin if taken with or up to 4 h after cholestyramine.

Cimetidine, cyclosporine, fluconazole, omeprazole, ranitidine
Fluvastatin serum levels may be increased.

Diclofenac, digoxin, glyburide, hydantoins
Serum levels of these agents may be increased.

Rifampin
Fluvastatin serum levels may be reduced.

Warfarin
Anticoagulant effect of warfarin may be increased.

本品若同時併用降脂膠囊、紅麴併用，可能會造成肝功能指數上升及血中肌酸激酶上升。

1.對本品過敏者

2.活動性肝疾病

3.孕婦及授乳婦

1.治療前做肝功能檢查治療後並複檢

2.嚴重的肌肉疼痛無力的副作用應考慮停藥